Olema Pharmaceuticals, Inc. (OLMA)

Olema Pharmaceuticals' stock price has been influenced by analyst ratings, including "Buy" and "Outperform", while Weiss Ratings reaffirmed a "sell" rating. The stock soared by 47% due to a second deal with Pfizer in September. The stock experienced a significant drop of approximately 30% in October 2025 after the presentation of ESMO 2025 data on palazestrant. Olema Pharmaceuticals granted stock options to new employees as part of an inducement plan in June 2025. In August 2025, the company reported quarterly earnings of ($0.51) per share, missing the consensus estimate of ($0.43). There has been significant insider selling over the past three months, with Director Cyrus Harmon selling shares in September 2025.

As a clinical-stage biopharmaceutical company without commercialized products, Olema Pharmaceuticals, Inc. does not currently have demand seasonality. Demand for its offerings will emerge upon successful completion of clinical trials and regulatory approvals.

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women's cancers. Their lead product candidate, palazestrant (OP-1250), is in Phase 3 clinical trials for recurrent, locally advanced, or metastatic ER+/HER2- breast cancer and is also being evaluated in combination with CDK4/6 inhibitors. Additionally, Olema is developing OP-3136, an orally available small molecule KAT6 inhibitor, which is in Phase 1 clinical trials for patients with ER+/HER2- metastatic breast cancer and other cancers.

Olema Pharmaceuticals, Inc. is headquartered in San Francisco, California, United States. Its operations are focused on research and development, with clinical trials potentially spanning multiple locations. The specific geographic market reach for commercialized products is not yet established.

Olema Pharmaceuticals' brand reputation has been tied to its clinical development progress and analyst sentiment. The company generally holds a "Moderate Buy" consensus rating from analysts. The market's reaction to clinical trial data indicates that reputation is highly sensitive to the perceived success of its drug candidates. A recent "sell" rating from Weiss Ratings also reflects a negative outlook.

The ownership structure of Olema Pharmaceuticals (OLMA) includes institutional, insider, and retail investors. Major institutional owners include Bain Capital Life Sciences Investors, LLC, Paradigm Biocapital Advisors LP, BVF Inc/il, BlackRock, Inc., Woodline Partners LP, Deep Track Capital, LP, Vanguard Group Inc, Logos Global Management LP, Janus Henderson Group Plc and Franklin Resources Inc. Institutional investors collectively hold a significant portion of the company's shares. Insiders own a notable percentage of the stock. Retail investors are also a substantial part of the ownership.